MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. by Joshi, Kaushal et al.
UCLA
UCLA Previously Published Works
Title
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Permalink
https://escholarship.org/uc/item/9767c30g
Journal
Stem cells (Dayton, Ohio), 31(6)
ISSN
1066-5099
Authors
Joshi, Kaushal
Banasavadi-Siddegowda, Yeshavanth
Mo, Xiaokui
et al.
Publication Date
2013-06-01
DOI
10.1002/stem.1358
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CANCER STEM CELLS
MELK-Dependent FOXM1 Phosphorylation is Essential for
Proliferation of Glioma Stem Cells
KAUSHAL JOSHI,a YESHAVANTH BANASAVADI-SIDDEGOWDA,a XIAOKUI MO,b SUNG-HAK KIM,a PING MAO,a
CENK KIG,i DIANA NARDINI,e,f ROBERT W. SOBOL,g,h LIONEL M.L. CHOW,e,f HARLEY I. KORNBLUM,c,d
RONALD WACLAW,e,f MONIQUE BEULLENS,i ICHIRO NAKANOa
aDepartment of Neurological Surgery, The James Comprehensive Cancer Center and bCenter for Biostatistics, The
Ohio State University, Columbus, Ohio, USA; cDepartment of Psychiatry and dDepartment of Molecular and
Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA; eCancer and Blood
Diseases Institute at Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; fDivision of
Experimental Hematology and Cancer Biology at Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio,
USA; gDepartment of Pharmacology & Chemical Biology and hDepartment of Human Genetics, University of
Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA; iLaboratory of Biosignaling & Therapeutics,
Department of Cellular and Molecular Medicine, KULeuven, Leuven, Belgium
Key Words. Neural stem cell • Cancer stem cell • Glioblastoma • Glioblastoma stem cell • PLK1
ABSTRACT
Glioblastoma multiforme (GBM) is a life-threatening
brain tumor. Accumulating evidence suggests that eradi-
cation of glioma stem-like cells (GSCs) in GBM is essen-
tial to achieve cure. The transcription factor FOXM1 has
recently gained attention as a master regulator of mitotic
progression of cancer cells in various organs. Here, we
demonstrate that FOXM1 forms a protein complex with
the mitotic kinase MELK in GSCs, leading to phospho-
rylation and activation of FOXM1 in a MELK kinase-de-
pendent manner. This MELK-dependent activation of
FOXM1 results in a subsequent increase in mitotic regu-
latory genes in GSCs. MELK-driven FOXM1 activation
is regulated by the binding and subsequent trans-phos-
phorylation of FOXM1 by another kinase PLK1. Using
mouse neural progenitor cells (NPCs), we found that
transgenic expression of FOXM1 enhances, while siRNA-
mediated gene silencing diminishes neurosphere forma-
tion, suggesting that FOXM1 is required for NPC
growth. During tumorigenesis, FOXM1 expression
sequentially increases as cells progress from NPCs, to
pretumorigenic progenitors and GSCs. The antibiotic Sio-
mycin A disrupts MELK-mediated FOXM1 signaling
with a greater sensitivity in GSC compared to neural
stem cell. Treatment with the first-line chemotherapy
agent for GBM, Temozolomide, paradoxically enriches
for both FOXM1 (1) and MELK (1) cells in GBM cells,
and addition of Siomycin A to Temozolomide treatment
in mice harboring GSC-derived intracranial tumors
enhances the effects of the latter. Collectively, our data
indicate that FOXM1 signaling through its direct interac-
tion with MELK regulates key mitotic genes in GSCs in
a PLK1-dependent manner and thus, this protein com-
plex is a potential therapeutic target for GBM. STEM
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most common pri-
mary malignant brain tumor and is highly aggressive and
therapy-resistant [1–3]. Even patients with well-demarcated
tumors in noneloquent areas that allow for gross-total resec-
tion at surgery and who respond well to first-line chemo-
therapies and radiotherapies frequently do not escape from
subsequent recurrence and ultimately die from disease pro-
gression. Therefore, there is an urgent need to develop
novel therapies to effectively target resistant GBM cells.
GBM is composed of mixed tumor cell populations includ-
ing tumor cells with stem cell properties, termed glioma
stem-like cells (GSCs) [4, 5] Accumulating evidence sug-
gests that stem cell properties of GSCs contribute to thera-
peutic resistance in GBM. Tumor stem cells are one, if not
the only, cellular target in GBM, and therapeutic develop-
ment targeting this subset of tumor cells may improve
patient survival [6].
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The transcription factor, FOXM1 is a member of the
Forkhead box (FOX) family that consists of more than 50
mammalian proteins with shared homology in the winged he-
lix DNA binding domain. Many genes within this family play
critical roles in cell cycle progression and cell fate decision.
Initial studies of FoxM1 characterized its role in liver devel-
opment [7]. Intriguingly, FoxM1 knockout mice fail to form
hepatocellular carcinoma in a carcinogenic induction model,
suggesting that FoxM1 is necessary for tumor initiation in the
liver [8]. Accumulated evidence suggests that FOXM1 is a
proto-oncogene with elevated expression in a number of
human cancers such as liver, ovarian, breast, prostate, colon,
and brain tumors including GBM. Downstream target path-
ways of FOXM1 include vascular endothelial growth factor
(VEGF), matrix metalloproteinase-2 (MMP-2), and b-catenin
[9–11], each of which promotes tumor formation and progres-
sion. FOXM1 enhances cancer stem cell self-renewal through
direct binding to b-catenin inducing nuclear localization and
transcriptional activity [10]. Taken together, abrogation of
FOXM1 signaling may provide multidirectional approaches
for controlling cancers including GBM.
Maternal embryonic leucine-zipper kinase (MELK) is a
serine/threonine kinase and is abundantly expressed in GBM
and various other cancers. Previously, we found that MELK
is highly expressed in GSCs derived from GBM samples and
its mRNA expression is inversely correlated with survival in
GBM patients [12]. In addition, small inhibitory RNA
(siRNA)-mediated MELK abrogation induces GSC apoptosis
in vitro with less inhibitory effects on normal neural progeni-
tor cells (NPCs) [12]. A recent study using a murine breast
cancer initiation model indicated that ablation of Melk elimi-
nates tumorigenesis in vivo; thus MELK is likely a therapeu-
tic target not only for GBM but also for other cancers [13].
Prior studies have suggested that both FOXM1 and
MELK play essential roles in cell cycle progression, cancer
cell growth, and maintenance of stem cell state of GBM. Fur-
thermore, MELK and FOXM1 are highly coexpressed and
coregulated in GBM suggesting that they are functionally
related. Therefore, we sought to test the hypothesis that
MELK and FOXM1 directly interact to regulate proliferation
of GSC [14]. In this study, we interrogated the physical inter-
action of FOXM1 and MELK, as well as the functional roles
of FOXM1-MELK signaling in GSCs. Here, we describe
novel mechanistic evidence that FOXM1 cooperates with
MELK to regulate the mitotic transcriptome in GSCs.
MATERIALS AND METHODS
Human Specimens and Tissue Culture
Neurospheres (NS) derived from 10 GBM samples and 1 fetal
brain were used in this study, as described previously [12, 15-
17]. Regarding the nine samples collected at The Ohio State
University (OSU), surgery was performed by I. Nakano and
E.A. Chiocca in the Department of Neurological Surgery, and
surgical specimens were processed for research under
approved protocols (IRB Number 2005C0075). GBM157 was
established in Dr. Kornblum’s laboratory at UCLA, as
described previously [18]. Established GSC cultures were cul-
tured in defined medium containing Dulbecco’s modified
Eagle’s medium (DMEM)/F12/Glutamax (Invitrogen, Carls-
bad, CA, http://www.invitrogen.com) supplemented with 2%
B27 supplements (Invitrogen) and 20 ng/ml epidermal growth
factor (EGF) and fibroblast growth factor-2 (PeproTech,
Rocky Hill, NJ, http://www.peprotech.com), as previously
reported [19]. Mouse neural progenitors were cultured from
the subventricular zone (SVZ) of the day 17 embryos, as
described previously [17]. 293T cells were obtained from the
American Type Culture Collection and cultured in DMEM
(Invitrogen) supplemented with 10% fetal calf serum (Sigma
Aldrich, St. Louis, MO, http://www.sigmaaldrich.com). For
more detailed methods, see Supporting Information.
Vectors
All the FOXM1 vectors (wild-type and mutants, S715A,
S724A, double mutant S715/724A,S678A, T596A, TSAA,EE
and the reporter 6x FoxM1) and PLK1 (wild-type and domi-
nant negative) were kindly provided by Dr. Zheng Fu of the
Virginia Commonwealth University. All MELK vectors were
described previously [20].
Phosphorylation Assay
FOXM1 cDNA was inserted in enhanced green fluorescent
protein (pEGFP)-C1 (Clontech, Palo Alto, CA, http://
www.clontech.com) for mammalian cell expression and
pet16b (Novagen) for bacterial expression. Flag-MELK and
pet16b-MELK1-340 were described previously [20]. HEK293
cells were transiently transfected with the indicated plasmids,
and cell lysis was performed as described [20]. The com-
plexes were trapped with GFP-trap beads (Chromotek, Ger-
many, http://www.chromotek.com) and analyzed for the pres-
ence of Flag-tag fused MELK with Flag antibody (Stratagene,
La Jolla, CA, http://www.stratagene.com). His-MELK1-340,
His-FOXM1, and His-cyclinA-CDK2 were expressed in bacte-
ria and purified as described previously [20, 21]. His-FOXM1
was phosphorylated in vitro by His-MELK1-340, His-MELK1-
340D150A, or His-cyclinA-CDK2 for 1 hour at 30C in a
buffer containing 25 mM Tris at pH 7.5, 0.1 mM [c-32P] ATP,
2 mM magnesium acetate, and 20 mM dithiothreitol (DTT).
Gene Expression Omnibus Profile and TCGA Data
Affymetrix Human Genome U133A Array was performed as
described previously. The data have been submitted to the
GEO database accession number GDS1815 [22, 23]. MELK
and FOXM1 expression (Affymetrix Human Genome U133A
Array) data were downloaded from the GDS1815 dataset and
analyzed for grade III glioma and GBM. The Cancer Genome
Atlas (TCGA) data are available through the TCGA Data Por-
tal at http://tcga-data.nci.nih.gov [24].
Drug Treatment
Siomycin A was obtained through the Developmental Thera-
peutics Program NCI/NIH. Siomycin A and ON-01910 (PLK1
inhibitor-selleck chemical Inc., Houston, TX, USA, http://
www.selleckchem.com) stock solution was prepared using
dimethyl sulfoxide (DMSO) (Sigma Aldrich). In each experi-
ment, DMSO alone was used in control samples at a concentra-
tion in between 0.1% and 1% and identical to the concentrations
of DMSO that was used in drug-treated cells in each experiment.
We confirmed that the growth of the cells we used in this study
is not significantly affected by DMSO at 1% or lower [18].
Statistics
Quantitative data are presented as means 6 SD, unless noted
otherwise in the figure legend. The numbers of replicates are
noted in the figure or legends. Comparison of mean values
between multiple groups was evaluated by an ANOVA fol-
lowed by Tukey’s test. When multiple comparisons were
involved, Holm’s method was used to adjust the multiplicities
to control the type I error rate that was less than 0.05 [25].
Spearman correlation coefficients (q) were used to assess the
correlation between FOXM1 and MELK expression in the
1052 MELK Dependent FOXM1 Phosphorylation in Glioma Stem Cells
GDS1815 microarray data and TCGA dataset [26]. Log-rank
tests were used to compare the survival probabilities between
groups in the xenograft mouse experiment. Comparison of
mean values between two groups was evaluated by v2 test or
t test. Log-rank analysis is used to determine statistical signif-
icance of Kaplan Meier survival curve. For all statistical
methods, a p-value less than .05 was considered significant.
For more detailed information, see Supporting Information.
RESULTS
FoxM1 Expression Is Restricted to NPCs in the
Mouse Brain
First, we investigated FoxM1 expression during brain ontog-
eny. Similar to Melk expression, FoxM1 expression in the
brain was predominantly detected during early and mid-
embryonic periods with a dramatic decline between embry-
onic day 15 (E15) and E17 (Fig. 1A). Expression of FoxM1
in the adult brain was below detectable levels by reverse tran-
scription polymerase chain reaction (RT-PCR). We then
examined FoxM1 expression in neural progenitor cultures
grown as NS derived from embryonic mouse cortices. FoxM1
expression was markedly high in proliferating NS, whereas its
expression levels declined dramatically in the prodifferentia-
tion—as indicated by expression of neuronal and glial
markers—conditions within 6 hours, the earliest time point
studied (Fig. 1B). These data suggest that, similar to Melk
expression, FoxM1 is preferentially expressed in proliferating
murine NPCs.
We then performed immunohistochemistry of FoxM1 with
mouse embryonic and adult brains. FoxM1 protein expression
was restricted to the germinal zone (GZ) of embryonic day 17
(E17) brains. The majority of FoxM1 (þ) cells were not colo-
calized with neuronal marker TuJ1 and vice versa (Fig. 1C,
Figure 1. FoxM1 expression is restricted in neural progenitor cells in the mouse brain. (A): Reverse transcription polymerase chain reaction
(RT-PCR) analysis for FoxM1 and Melk expression during brain development. (B): RT-PCR analysis for FoxM1 and Melk in neural progenitor
cells with or without differentiation. Expression is compared with the differentiation markers for neurons (neurofilament heavy chain [Nfh]),
astrocytes (Gfap), and oligodendrocytes (proteolipid protein [Plp]). For (A) and (B), Gapdh is used as internal control. (C): Left panels, top two
images indicate immunohistochemistry for FoxM1 (green) and Sox2 (red) in mouse brains of embryonic day 17 (E17). Lower four pictures, im-
munofluorescence for FoxM1 (green) and Tuj1 (red) in mouse brains of E17. Original magnification is 10 and 40. Scale bars ¼ 100 and 20
lm. (a) CZ, (b) GZ, (c) ST represents magnified pictures of FOXM1 (green) and Tuj-1 (red). Original magnification is 10 and 40. Scale bars
¼ 100 and 20 lm. Right panels represent immunohistochemistry for FoxM1 (green), Gfap (red), BrdU (red), and Dcx in brains of the postnatal
mouse day 30. Original magnification is 20–40. Scale bars ¼ 50–20 lm, respectively. (D): Immunohistochemistry of FOXM1 (brown) in
adult mouse brain at the SVZ (left panel) and at the subgranular zone (right panel). Original magnification is 40. Scale bars ¼ 20 lm. (E): Bar
graph representing the relative number of NS formed from EGFP- or FoxM1-expressing NS derived from mouse E17 cerebral cortices. Asterisks
(*) indicate statistical significance by t test. (F): Left panel exhibiting diagram of two different isoforms of FoxM1 protein. Right panel indicating
the relative number of NS formed from FoxM1a or FoxM1a/b siRNA transfected NS derived from mouse E17 cerebral cortices. NS forming
assay was performed in triplicate in 96-well plate and repeated three times independently. Abbreviations: BrdU, Bromodeoxyuridine; CC, corpus
callosum, CZ, cortical zone; DCX, doublecortin; DC, differentiated cells; EGFP, enhanced green fluorescent protein; ES, embryonic stem cells;
E, embryonic brain; GFAP, glial fibrillary acidic protein; GZ, germinal zone; NS, neurospheres; P, postnatal brain; SVZ, subventricular zone; ST,
striatum; V, ventricle; VZ, ventricular zone.
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left panels; Supporting Information Fig. S1). In contrast, we
observed extensive overlap of FoxM1 (þ) cells with Sox2
(þ) cells in the GZ. In brains at the postnatal day 30 (P30),
FoxM1 expression was restricted to the proliferative zones
lining the ventricles and was not colocalized with glial fibril-
lary acidic protein (GFAP), suggesting that FoxM1 is unlikely
to be expressed in differentiated astrocytes or type B neural
stem cells (NSCs) (Fig. 1C, right panels). In addition, there
was no detectable coexpression of FoxM1 and the neuroblast
marker Dcx. On the other hand, FoxM1 was expressed by
proliferating cells, as indicated by colocalization with BrdU.
Taken together, these data suggest that the majority, if not all,
FoxM1 (þ) cells are rapidly proliferating type C progenitor
cells in the SVZ. When FoxM1 expression was evaluated in
the other neurogenic region, the subgranular zone (SGZ) of
hippocampus, very few cells, if any, in the SGZ express
FoxM1 at P30 (Fig. 1D).
FoxM1 Regulates NPC In Vitro
To determine the function of FoxM1 in NPCs, we assessed the
effects of transgenic expression and silencing of the active
FoxM1 isoform b on NS derived from E17 cerebral cortices.
These neural progenitors were transfected with either the expres-
sion vectors or double-stranded RNAs designed to be siRNA for
FoxM1 (isoform b) or controls. For knockdown of FoxM1, we
designed two control siRNAs that silence either nontarget
sequence or the transcription repressor region of FoxM1 isoform
a, that is not present in the translationally active form of FoxM1,
isoform b (Fig. 1E) [27]. Overexpression of FoxM1 (isoform b)
resulted in a twofold enhancement of NS formation (Fig. 1E;
Supporting Information Fig. S2). Although siRNA-mediated
silencing of the inactive FoxM1 (isoform a) did not alter the
growth of NS compared with the nontarget control, siRNA
directed against the common region of FoxM1 (isoforms a and
b) resulted in a significant decrease in NS numbers (Fig. 1F, right
panel; Supporting Information Fig. S2). Collectively, these data
suggest that FoxM1 is essential for the growth of murine NPCs
derived from embryonic brains in vitro.
FoxM1 Expression Is Markedly Elevated During
Gliomagenesis
Accumulating evidence suggests that GSCs and their somatic
counterparts, NPCs, share various fundamental signaling path-
ways to regulate their self-renewal and proliferation. We
therefore sought to determine the role of FoxM1 in GBM-like
tumors and GSCs in mice harboring conditional inactivation
of the human GBM-relevant tumor suppressors p53, Nf1, and
Pten [28]. In this model, Nestin promoter-driven Bromodeox-
yuridine (BrdU)(þ) cells along the ventricular wall are the
cells of origin for the cortical GBM-like tumors formed in
adult mice [28]. When we compared FoxM1 staining of the
SVZ of wild-type mice and genetically engineered mutant
GBM mouse brains, we observed sequential elevation of
FoxM1 expression along the ventricular wall during the
course of tumorigenesis (Fig. 2A; Supporting Information Fig.
S3). When FoxM1 expression was compared between normal
brain regions versus tumor areas of individual mice, tumors
had more than 200-fold higher expression than normal brain
regions (Fig. 2B). We then compared FoxM1 expression in
NS derived from the SVZ of wild-type mice and GBM-like
tumors. FoxM1 mRNA levels were 2.5-fold greater in GBM
NS than in normal NS, indicating that FoxM1 expression is
elevated in GSCs compared to NPCs in vitro (Fig. 2C) [29].
The FOX family transcription factors play a crucial role
in organ development and cancer initiation and propagation in
a context-dependent manner [30, 31]. To determine which
members of the FOX gene family are upregulated in GSCs,
we evaluated expression levels of all the FOX genes in the
transcriptome microarray data derived from 30 patient-derived
GSC samples as well as 4 normal astrocytes primary cultures
(Fig. 2D). Among 51 FOX family members, FOXM1 exhib-
ited strikingly higher expression in GSCs in comparison to
normal astrocytes, unlike any other FOX family members. In
all of the tested 10 GSC samples, we observed 6–12-fold
higher FOXM1 expression by quantitative RT-PCR compared
to astrocytes (Fig. 2E). CD133 expression on the cell surface
is associated with cancers stem cells in some, if not all, GBM
tumors [1, 4, 16, 32-34]. We further performed cell sorting by
using CD133 marker and separated CD133 (þ) and CD133
() cells for GBM157 and GBM528 GSCs. qRT-PCR demon-
strated higher expression of FOXM1 and MELK in CD133
(þ) cells than CD133 () cells in both samples (Fig. 2F).
We then examined FOXM1 protein expression in human
GSCs. In agreement with previous studies, immunohistochemis-
try of a human GBM specimen demonstrated strong immunore-
activity for FOXM1 in the nuclei of GBM cells (Supporting In-
formation Fig. S4) [35]. Immunocytochemistry of dissociated
GBM NS demonstrated that FOXM1 was colocalized with the
stem cell-associated markers including Nestin and SOX2 but not
with the differentiation markers, TuJ1 or GFAP (Fig. 2G). Pro-
tein expression analysis by flow cytometry also yielded similar
results. Similar to the higher proportion of tumor cells expressing
the NSC-associated protein SOX2 and in contrast to the lower
proportion of tumor cells expressing the astrocytic marker GFAP
in GSCs in serum-free conditions, FOXM1 (þ) cells were pre-
dominantly detected in GSCs in serum-free medium (GBM
NSs), when compared to GBM cells propagated in serum-con-
taining medium (SPGCs) (Fig. 2H; Supporting Information Fig.
S5). Subsequently, we analyzed FOXM1 promoter activity in
GSCs and non-GSCs in GBM30. GSCs manifested a signifi-
cantly higher FOXM1 promoter activity in comparison to SPGCs
(Supporting Information Fig. S6). Taken together, FOXM1
expression and activity are substantially elevated in GSCs com-
pared to SPGCs and normal cells in mouse and human brains.
FOXM1 Is a Substrate for MELK
Prior studies have suggested that both FOXM1 and MELK
play essential roles in the cell cycle progression, cancer cell
growth, and maintenance of stem cell state of GBM [18, 20,
32, 35, 36]. Nonetheless, no studies have demonstrated a
direct molecular interaction of MELK and FOXM1. We there-
fore sought to elucidate the potential molecular interaction of
FOXM1 and MELK. First, we used the TCGA array data set
(GEO database accession number GDS1815) to determine the
similarities of the expression profiles between FOXM1 and
MELK in high-grade glioma (Fig. 3A). Using 24 grade III gli-
oma samples and 56 GBM samples, we found that FOXM1
RNA expression in individual tumors was correlated with
MELK expression (p< .001). Significant correlation was also
observed in newly diagnosed and recurrent GBM patient sam-
ples at RNA levels (Supporting Information Fig. S7). We then
sought to expand our analysis of their expression in GBM tis-
sues through The Cancer Genome Atlas (TCGA), a publicly
available repository which has accumulated comparative
genomic hybridization, gene expression, and DNA methyla-
tion analyses for 218 GBM samples [24]. Using this database,
coexpression of MELK in GBM tumor samples was con-
firmed (p< .0001) with FOXM1 expression. Immunocyto-
chemistry with patient-derived GBM NS (GBM30) exhibited
colocalization of FOXM1 with MELK within individual cells
(72.5% 6 2.4% colocalization in Fig. 3B).
Since FOXM1 and MELK are expressed in the same cells,
we next investigated whether levels of MELK influence
FOXM1 expression and vice versa (Fig. 3C; Supporting
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Information Fig. S8). Both RT-PCR and Western blot demon-
strated that MELK expression is not affected by FOXM1 trans-
genic expression or silencing. Likewise, RT-PCR analysis dem-
onstrated that neither MELK overexpression nor knockdown
affected FOXM1 expression. We then asked whether FOXM1
physically interacts with MELK. HEK 293 cells overexpressing
both Flag-tagged MELK and the fusion protein of FOXM1 and
EGFP or EGFP alone (control) were subjected to EGFP trap,
followed by Western blot with MELK or Flag antibody (Fig.
3D, upper panel; Supporting Information Fig. S9). Cells co-
overexpressing MELK and FOXM1 exhibited a stronger band
for MELK than the control samples, implying a physical inter-
action between MELK and FOXM1 protein. This protein–pro-
tein interaction is likely dependent on MELK kinase activity, as
the band intensity for the co-immunoprecipitation (IP) of the
catalytically dead MELK mutant (D150A) was substantially
diminished. Furthermore, we confirmed the direct interaction of
these two proteins with an in vitro interaction study using
recombinant purified FOXM1 and the purified N-terminal
MELK-fragment (amino acid 1–340) but not with the C-termi-
nal fragment (not shown).
We next asked whether recombinant MELK phosphorylates
FOXM1 (Fig. 3D, lower panels). Purified recombinant FOXM1
was incubated with or without the purified kinase domain of
Figure 2. FoxM1 expression is markedly elevated during gliomagenesis. (A): Representative images of immunohistochemistry for FoxM1 (brown)
in the SVZ of wild-type mice, SVZ of pretumorigenic Mut6 mice, and GBM-like tumors in cerebral cortex or normal areas in brain stem in Mut6
mice. Original magnification is 10. Scale bars ¼ 100 lm. Magnified images are shown below. Original magnification is 40. Scale bars ¼ 20 lm.
(B): Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis for FoxM1 expression in GBM tissues in Mut6 mice compared
to normal side brain tissues derived from the same mice. Asterisks (*) indicate statistical significance by t test. Experiment repeated in three Mut-6
mouse-derived GBM tissues. (C): Phase bright representative images of NS derived from either normal SVZ or GBM-like tumors developed in Mut6
mice. Original magnification: 10. Scale bars ¼ 100 lm. Lower panel indicates qRT-PCR data for FoxM1 expression in NS derived from GBM-like
tumors (GBM NS) in Mut6 mice or normal SVZ (normal NS). Asterisk (*) indicates statistical significance by t test. Experiments were done in tripli-
cate and repeated three times independently. (D): Microarray analysis of relative FOX genes family expression in GBM (n ¼ 30) compared to normal
astrocytes cultures (n ¼ 4). Expression of astrocytes was normalized as one. Expression of FOXM1 is shown in red. (E): Relative expression of
FOXM1 of 10 GSCs samples compared to normal astrocytes cultures. FOXM1 expression of normal astrocytes was normalized as one. (F): Relative
mRNA expression of FOXM1 and MELK in GBM157 and GBM528 CD133 (þ) and CD133 () cells collected after cell sorting (n ¼ 3). (G): Repre-
sentative immunocytochemistry of GBM NS and GBM cells propagated in serum-containing medium (SPGCs) derived from GBM30. Cells were
double-stained for FOXM1 (red) in combination with one of the following neural progenitor cell markers Nestin, SOX2 and differentiation markers
TuJ1, GFAP (green). Hoechst dye is used for nuclear staining (blue). Original magnification: 40. Scale bars ¼ 20 lm. Right panel indicates of the
proportions of FOXM1 positive cells coexpressing SOX2, Nestin, GFAP, and TuJ1 positive cells. For quantification, GBM30 sample were used and
the experiment was repeated four times. (H): Flow cytometry analysis for the expression of FOXM1, SOX-2, and GFAP using GBM NSs and SPGCs,
both of which are derived from GBM30. Abbreviations: FITC, fluorescein isothiocyanate; FSC, forward scatter; GFAP, glial fibrillary acidic protein;
GBM, glioblastoma multiforme; NS, neurosphere; SPGC, serum-propagated GBM cells; SVZ, subventricular zone.
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MELK in an in vitro phosphorylation assay. In parallel, we used
purified CDK2/cyclin A kinase, a known FOXM1 kinase, as a
positive control [37]. The autoradiogram clearly shows in vitro
phosphorylation of FOXM1 by MELK and CDK2/cyclinA. In
addition, FOXM1 phosphorylation was not observed when incu-
bated with kinase dead mutant MELK D150A. The same amount
of FOXM1 was present in all conditions, as is shown on the cor-
responding Coomassie staining. Collectively, these data indicate
that MELK directly interacts with FOXM1 and thereby, phos-
phorylates FOXM1 in a kinase dependent manner.
MELK Activates FOXM1 Transcriptional Activity
Leading to Upregulation of Mitotic Gene Expression
To understand more in depth the molecular mechanism of
MELK-dependent FOXM1 signaling, we investigated whether
MELK regulates FOXM1 transcriptional activity using the 6
FOXM1-TATA-luciferase reporter plasmid. Transgene expres-
sion of wild-type FOXM1 alone activated its transcriptional
activity, suggesting self-activation in GBM30 GSCs (Fig.
4A). Transgenic expression of wild-type MELK significantly
Figure 3. FOXM1 is a substrate for MELK. (A): Comparison of MELK and FOXM1 expression profile (Affymetrix Human Genome U133A
Array) indicates statistically significant correlation of the expression of these two genes in grade III glioma (left) (n ¼ 24) and in GBM (middle)
(n ¼ 56). The Cancer Genome Atlas (TCGA) analysis of MELK and FOXM1 expression profile in 218 GBM patient samples indicates statistical
significance (right panel). (B): Representative images of immunocytochemistry with GBM30 neurospheres for FOXM1 (red), MELK (green).
Hoechst dye for nuclear staining (blue). Original magnification: 40. Scale bar ¼ 20 lm. For quantification, GBM30 samples were used and the
experiment was repeated four times. (C): Reverse transcription polymerase chain reaction (RT-PCR) analysis for MELK and FOXM1 expression
in GBM neurospheres treated with siRNA targeting three different sequences for FOXM1 (left). RT-PCR analysis for MELK and FOXM1 expres-
sion in GBM neurospheres treated with different doses of siRNA targeting MELK (right) n ¼ 5. (D): Upper panel: Overexpression of Empty-
EGFP (control) þ MELK-Flag (Flag-MELK), EGFP-FOXM1 þ MELK-Flag, or EGFP-FOXM1 þ MELK D150A-Flag plasmids in HEK293
cells are processed to GFP-trap followed by immunoblotting with anti-Flag antibody. Middle panel: Autoradiogram displaying in vitro phospho-
rylation of FOXM1 by the kinase domain of MELK (1–340). Lane 1: FOXM1 þ ATP-Mg (no kinase); lanes 2 and 6: FOXM1 þ ATP-Mg þ
MELK (1–340); lane 3: FOXM1 þ MELK (1–340) (no ATP-Mg); lane 4: FOXM1 þ ATP-Mg þ CDK2/CyclA; lane 5: FOXM1 þ ATP-Mg þ
CDK2/CyclA þ roscovitine; lane 7: FOXM1þ ATP-Mg þ MELK1–340(D150A). Lower panels: Coomassie staining of the samples subjected to
autoradiography. Abbreviations: GBM, glioblastoma multiforme; IP, immunoprecipitation.
1056 MELK Dependent FOXM1 Phosphorylation in Glioma Stem Cells
enhanced FOXM1 self-activation in a concentration-dependent
manner (Fig. 4A). On the other hand, transgenic expression of
the kinase dead mutant MELK D150A eliminated FOXM1
self-activation in a concentration-dependent manner. Since
FOXM1 is known to regulate the transcriptional network of
genes essential for mitotic progression (e.g., Aurora B kinase,
CENPA, Survivin, and CyclinB1), we examined whether the
FOXM1-MELK complex had any effect on mitotic regulators
in GBM30 GSCs. Cotransfection of FOXM1 with MELK
resulted in a marked elevation of the key mitosis genes (Fig.
Figure 4. MELK phosphorylates FOXM1 and regulates FOXM1 activity, leading to upregulation of mitotic gene expression. (A): Graph indi-
cating the FOXM1 promoter activity in 293T cells transfected with the 6FOXM1 TATA-luciferase plasmid together with expression vectors
encoding wild-type FOXM1 and increasing amounts of plasmids encoding either WT MELK or kinase-dead mutant form of MELK (D150A).
The experiment was performed in triplicate in 96 well plates and repeated three times independently. (B): Relative mRNA expression levels of
Survivin, CyclinB1, CDC25B, and Aurora B by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in GBM30 cells trans-
fected with GFP, FOXM1, FOXM1 þ WT MELK, and FOXM1 þ MELK D150A mutant. qRT-PCR was performed in triplicate and repeated
three times independently. Abbreviations: EGFP, enhanced green fluorescent protein; WT, wild type.
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4B) [38]. In contrast, MELK D150A did not influence
FOXM1-mediated mitotic transcriptional expression. Taken
together, MELK kinase activity regulates phosphorylation and
self-activation of FOXM1, leading to enhanced mitotic gene
expression in GSCs.
MELK-Driven Phosphorylation of FOXM1 Is PLK1
Dependant
We then sought to determine the mechanisms that regulate
FOXM1 activation by MELK in GSCs. A recent study by Fu
et al. [39] demonstrated that, similar to MELK, PLK1 binds
and phosphorylates FOXM1 leading to FOXM1 activation and
increased gene expression required for mitotic progression in
hepatocellular carcinoma cells. We therefore sought to dissoci-
ate the molecular signaling mechanisms of MELK-driven
FOXM1 phosphorylation and PLK1-driven FOXM1 phospho-
rylation in GSCs. First, we used the PLK1 specific inhibitor
ON01910 together with overexpression of FOXM1, MELK,
and/or PLK1 and evaluated FOXM1 promoter activity (Fig.
5A). After confirming the elimination of PLK1-driven FOXM1
activation by ONO1910, we found that ONO1910 also elimi-
nates FOXM1 activation driven by MELK in a dose-dependent
manner (Fig. 5A). In order to exclude the possibility of an off-
target effect by pharmacological inhibition, we then tested the
effect of the PLK1 dominant negative mutant (PLK1 DN) on
MELK-mediated FOXM1 activation. Similar to the results with
the pharmacological inhibition, forced expression of PLK1 DN
eliminated MELK-driven FOXM1 activation in GBM30 GSCs
(Fig. 5B). To further confirm these results, we used the consti-
tutive active form of FOXM1 (FOXM1 EE as PLK1-driven
phosphomimics) to assess whether MELK D150 mutant is able
to eliminate FOXM1EE-driven FOXM1 activation in 293T and
GBM30 GSCs (Fig. 5C). Unlike the MELK D150A-induced
elimination of FOXM1 wild-type-driven self-activation, MELK
D150A failed to diminish FOXM1 activation driven by
FOXM1 EE in both 293T cells and GBM30 GSCs. Taken to-
gether, these data suggest that MELK-regulated FOXM1 activa-
tion is dependent on PLK1 in GSCs.
We next asked whether MELK-driven FOXM1 activation is
regulated by either the initial binding event of PLK1 to
FOXM1 or the secondary trans-phosphorylation of FOXM1 fol-
lowing PLK1-FOXM1 binding. Specifically, Ser 715 and Ser
724 of the FOXM1 protein were mapped to be the major trans-
phosphorylation sites and Thr-596 and Ser-678 were mapped to
be the PLK1 binding sites [39]. A single mutation of Ser 715 or
Ser 724 partially reduces the FOXM1 self-activation, whereas a
transgenic expression of the double mutation results in com-
plete abolishment of FOXM1 trans-activation [39]. Mutation of
one of the two residues resulted in only a partial decrease in
MELK-enhanced FOXM1 self-activation in both 293T cells
and GBM30 GSCs (Fig. 5D). On the other hand, introducing
the double mutation led to a major reduction in MELK-depend-
ent FOXM1 transcriptional activity nearly to the level resulting
from the loss of MELK kinase activity induced by the D150A
mutation (Fig. 5D). We then performed the same experiments
with the FOXM1 mutant vectors lacking the ability of PLK1 to
bind FOXM1 either partially (single mutation vectors) or com-
pletely (double mutation vector) (Fig. 5E). Transgenic expres-
sion of the double mutation vector (FOXM1 596/678), but not
the single mutation vectors (FOXM1 T596A and S678A),
almost completely abrogated MELK-driven FOXM1 activation
both in 293T cells and GSCs. Taken together, these data indi-
cate that the MELK-driven FOXM1 activation is dependent on
both the initial binding and subsequent trans-phosphorylation
events by PLK1 in GSCs.
Siomycin A Abrogates FOXM1-MELK Interaction
Previously, the thiazole antibiotic Siomycin A was identified
as a FOXM1 inhibitor by diminishing its protein and mRNA
abundance, and we recently discovered that Siomycin A also
reduced MELK expression in GSCs in vitro [9, 18, 40]. Con-
sistent with these findings, flow cytometry demonstrated that
Siomycin A reduced the proportions of FOXM1 (þ) and
MELK (þ) cells in GBM NS in a dose-dependent manner
(Fig. 6A). We then investigated the effect of Siomycin A on
FOXM1 activity driven by FOXM1 and/or the FOXM1-MELK
complex (Fig. 6B). We treated GBM30 GSCs with 0.1 lM or
0.5 lM of Siomycin A after transfection. Similar to the protein
expression, FOXM1 activity was almost abolished, declining
to basal levels at 48 hours post-treatment with 0.5 lM of Sio-
mycin A, suggesting that Siomycin A abrogates FOXM1 activ-
ity driven by FOXM1 itself as well as MELK-driven FOXM1
phosphorylation. Next we evaluated whether restoring
FOXM1 and MELK rescues Siomycin A-induced mitotic
arrest in GSCs (Fig. 6C). In agreement with previous studies
using other cancer cells, GSCs increased the proportion of
cells in the G2/M phase when treated with 0.5 lM of Siomy-
cin A (cells in G2/M phase: 18.72%–34.23%) [40, 41]. This
data indicated that Siomycin A induces G2/M arrest of GSCs.
Overexpression of FOXM1 with MELK, but not FOXM1 or
MELK alone, rescued the Siomycin A-induced G2/M arrest of
GBM30 GSCs (cells in G2/M phase: 34.23%–21.74%). These
data provided supporting evidence for the critical role of the
FOXM1-MELK complex in mitotic progression of GSCs.
Since FOXM1 levels were markedly higher in GSCs com-
pare to NPCs (Fig. 2), we reasoned that the dependence of
GSCs on FOXM1 would be greater than that of NPCs.
Indeed, when we treated mouse and human GSC cultures
(derived from Mut 6 mice and GBM30, respectively) and
NPC cultures (derived from wild-type mice and a 16-week-
old fetus-16wf, respectively) with varying doses of Siomycin
A, GSCs derived from both species were 15-fold more sensi-
tive to Siomycin A than NPCs, suggesting that pharmacologic
inhibition of FOXM1 signaling by Siomycin A has stronger
impact on in vitro growth of GSCs than NPCs (Fig. 6D).
Combined Treatment of Temozolomide with Siomy-
cin A on GSCs-Derived Mouse Tumors Yields Better
Survival than Monotherapy with Temozolomide
Accumulated evidence suggests that GSCs are relatively re-
sistant to Temozolomide chemotherapy partly due to elevated
expression of the drug resistance genes compared to non-
GSCs [42–45]. We found that Temozolomide treatment of
GBM30 GSCs paradoxically increases the expression of
FOXM1 and MELK in a dose-dependent manner (Fig. 7A).
These findings are consistent with the hypotheses that Temo-
zolomide treatment spares FOXM1 and MELK expressing
GSCs or promotes the appearance of a GSC-like phenotype.
We then investigated the effect of combination treatment
with Temozolomide and Siomycin A on GSCs-derived mouse
tumors in vivo (Fig. 7B–7E). Xenografting GBM30 NS
resulted in the formation of GBM-like tumors in immunocom-
promised mouse brains. Similar to human GBM, the
xenograft-derived tumors exhibited massive intratumoral hem-
orrhage, necrosis, and densely packed tumor cells with hyper-
chromatic nuclei surrounding tumor vessels (Fig. 7B).
Immunohistochemistry of mouse tumors at 2 days post-
Siomycin A injection demonstrated a significantly reduced
fraction of Ki-67(þ) proliferating cells compared to control-
treated mouse tumors (Fig. 7C). In order to determine the
effect of Siomycin A treatment on GSCs in vivo, we cultured
NS forming cells of treated and control tumors. Tumors
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assayed at 2 days post-Siomycin A injection had significantly
fewer NS-forming cells compared to the control tumors (Fig.
7D). These data suggest that Siomycin A has a potent inhibi-
tory effect on survival and proliferation of GSCs in vivo. Sub-
sequently, we assessed if Siomycin A treatment has any sur-
vival benefit on Temozolomide-treated mouse tumors. When
the tumors were treated with Temozolomide alone, median
survival of tumor-bearing mice was prolonged from 11.5 days
to 22.5 days (Fig. 7E). The combined treatment with Temozo-
lomide and Siomycin A exhibited further benefit on mouse
survival (median survival to 28 days) (DMSO control vs.
TemozolomideþSiomycin A: p< .001).
Finally, we used the tumor slice culture method to assess
Siomycin A treatment on surgical GBM specimens [46].
Patient-derived GBM slice cultures were treated with DMSO,
Temozolomide, or Siomycin A, and the effects were measured
16 hours post-treatment. H&E staining of the slice cultures
demonstrated that the procedures did not destroy the cytoarchi-
tecture of GBM tumors (Supporting Information Fig. S10).
Immunohistochemistry with a proliferation marker, Ki67 dem-
onstrated vast numbers of proliferating tumor cells in DMSO-
treated samples, but not in Temozolomide- or Siomycin A-
treated tissues (Supporting Information Fig. S11). In turn,
immunohistochemistry for apoptosis marker activated Caspase-
3 displayed significantly higher number of apoptotic cells in
Siomycin A-treated samples, but not in DMSO- or Temozolo-
mide-treated cultures (Supporting Information Fig. S11).
DISCUSSION
Molecular signaling between protein kinases and transcription
factors plays vital roles in tumor development and mainte-
nance [47]. Here, we demonstrate the first evidence that the
transcription factor/oncogene FOXM1 forms a protein
Figure 6. SM abrogates MELK-driven FOXM1 activity and inhibits growth of glioma stem-like cells (GSCs) but not normal progenitors in mouse
and human. (A): Flow cytometry analysis on GBM30 spheres treated with either DMSO or SM. The upper panels indicate the proportions of
FOXM1 (þ) cells in GBM30 spheres with indicated dose of SM treatment for 72 hours. The lower panels display the proportions of MELK (þ)
cells in each condition. Experiment was repeated three times and similar expression pattern was observed. (B): Graph indicating the FOXM1 pro-
moter activity in indicated cells transfected with the plasmids encoding for FOXM1 wild-type (WT) with MELK WT or kinase dead D150A. The
cells were then treated with indicated doses of SM after transfection for 48 hours, followed by detection of FOXM1 activity by luciferase assay.
(C): Graph showing cell cycle analysis with flow cytometry of GBM30 GSCs. The cells were treated with either control (DMSO 1%), SM (500
nM), FOXM1 wild-type overexpression together with SM (500 nM), MELK wild-type overexpression together with SM (500 nM) or MELK, and
FOXM1 wild-type overexpression together with SM (500 nM) for 48 hours. (D): Left panel indicates the relative neurosphere numbers formed from
mouse subventricular zone or GBM-like tumors with SM (500 nM) treatment or DMSO. The right panel shows the relative neurosphere numbers
formed from GBM30 GSCs and normal spheres (16wf).The different numbers of cells were seeded in each well, as shown on x-axis. DMSO con-
centration is 1% and SM was 500 nM. The experiments were done in triplicates using 96 well plates and repeated three times. Abbreviations:
DMSO, dimethyl sulfoxide; FITC, fluorescein isothiocyanate; FSC, forward scatter; GBM, glioblastoma multiforme; SM, Siomycin A.
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complex with a serine/threonine kinase MELK and that
FOXM1 serves as a substrate of MELK in cancer cells, and
MELK-regulated FOXM1 phosphorylation controls FOXM1
activity and induces the expression of downstream mitotic
regulators. The transcription factor FOXM1 is a master regu-
lator for cell cycle progression and is overexpressed in a num-
ber of human cancers including GBM [48]. The protein kinase
MELK is also abundantly expressed in various cancers includ-
ing GBM and plays a pivotal role in survival of cancer cells
and cancer stem cells [12]. Recent studies have shed light on
FOXM1 signaling in GBM and GSCs [10]. FOXM1 interacts
with the promoter of the VEGF gene regulating its activation,
which contributes to GBM tumor angiogenesis [49]. Another
study by Zhang et al. elegantly showed that FOXM1 is a
downstream component of canonical Wnt-signaling and
directly binds to b-catenin, inducing its nuclear translocation
and transcriptional activation [39]. This study demonstrates
the first evidence that FOXM1 directly interacts and is
Figure 7. Combined treatment of TMZ with SM on glioma stem-like cell (GSC)-derived mouse tumors yields better survival than monotherapy
with TMZ. (A): Flow cytometry analysis for FOXM1 (upper panels) and MELK (lower panels) with GBM30 SPGCs (serum-propagated GBM
cells) treated with varying doses of TMZ for 72 hours. Experiment was repeated three times for confirmation of results. (B): Representative
images of mouse brains with intracranial xenograft tumors derived from GBM30 neurospheres (left top panel). Middle and lower pictures indicate
H&E staining. N indicates necrotic area in the tumor. Original magnifications: 2 (middle panel) and 10 (lower panel). Scale bar ¼ 500 lm
(middle panel) and 100 lm (lower panel). (C): Ki-67 immunohistochemistry of mouse tumors treated with either DMSO or SM. Mice were sacri-
ficed at 2 days post-SM treatment. Original magnifications: 20. Scale bars ¼ 50 lm. Graph (right) indicating the proportion of Ki-67(þ) cells
in DMSO- and SM-injected tumors analyzed by Image J software. (n ¼ 4 for each group) Asterisk (*) indicates statistical significance by t test.
(D): Graph indicating the relative neurosphere numbers derived from mouse tumor tissues following DMSO and SM treatment for 2 days. (n ¼
3) Asterisk (*) indicates statistical significance by t test. (E): Kaplan Meier survival curve of mice harboring GBM30 neurosphere-derived tumors
treated with DMSO (control), TMZ (10 mg/kg), or TMZ (10 mg/kg) combined with SM injection (2.5 nM). Table (right) indicates the mean and
medial survival periods of the three groups. Abbreviations: DMSO, dimethyl sulfoxide; FITC, fluorescein isothiocyanate; FSC, forward scatter;
SM, Siomycin A; TMZ, Temozolomide.
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phosphorylated by MELK in GSCs, further providing evi-
dence for a role of FOXM1 signaling in GBM. Our data indi-
cate that both phosphorylation of FOXM1 protein and tran-
scriptional activity of FOXM1 depend on MELK kinase
activity. Intriguingly, FOXM1 activation driven by MELK is
dependent on both the priming event of the complex forma-
tion of FOXM1 with PLK1 and the subsequent trans-activa-
tion of FOXM1 by PLK1.
Despite the advances presented here, open questions still
remain. First, it is not clear whether the MELK/FOXM1 pro-
tein complex plays a positive role in cancers or cancer stem
cells in other organs. Second, it is undetermined whether
MELK-mediated signaling is associated with the other pro-
teins that regulate, or are regulated by, FOXM1 in cancer
cells. Future studies are needed to elucidate these questions.
The cell of origin for GBM is still debatable, although the
concept has been evolving. Here, we used a mouse model of
gliomagenesis by ablation of key tumor suppressor genes in
NPCs causing formation of GBM-like tumors in cerebral cor-
tices. Our data indicated that FOXM1 signaling is operative
in NPCs of the developing brains in vivo. Immunohistochem-
istry exhibited that abundance of FOXM1 protein is progres-
sively elevated as cells progress from the neural progenitor
stage through pretumorigenic progenitors to GSC. Sensitivity
of GSCs to Siomycin A was markedly higher than that of
NPCs. Taken together, these data indicate that GSCs are more
dependent on FOXM1 signaling compared to NPCs. However,
it remains unknown whether activation of FOXM1 signaling
alone is sufficient for gliomagenesis and whether FOXM1 sig-
naling plays a critical role in oligodendrocyte precursor-
derived gliomagenesis. Future studies could help address these
questions.
An important therapeutic implication of the present data is
that combined therapy of mouse xenografted tumors with
Temozolomide and Siomycin A resulted in diminished NS-
forming GSCs in tumors and provided an additional benefit
on mouse survival. Although eradication of cancer stem cells
appears to be essential for the cure of cancers, recent studies
also suggest that non-cancer stem cells acquire cancer stem
cell phenotype when challenged by stressors such as ionizing
radiation and chemotherapies [50]. To achieve cure of a can-
cer, eradication of the rare population of tumor cells that are
considered as existing cancer stem cells may not be sufficient;
instead, combination of non-cancer stem cell-targeted thera-
pies and cancer stem cell-targeted therapies appears to be
mandatory. Our data indicate that Temozolomide treatment
increased, while Siomycin A decreased, both FOXM1 and
MELK expression in GSCs. One interpretation of these data
is the preferential eradication of non-stem tumor cells and
subsequent enrichment of GSCs after treatment (selection of
therapy-resistant tumor cell population; the clonal evolution
theory). Alternatively, Temozolomide may induce phenotypic
changes of the treated GBM cells and may increase FOXM1
and MELK expression (the molecular evolution theory). It is
also possible that both theories are true. Future studies will
address this open question.
CONCLUSION
In this study, we demonstrated that the oncoprotein FOXM1
is regulated by the mitotic kinase MELK for its phosphoryla-
tion and autoactivation via a direct interaction in GSCs.
Although FOXM1 is restrictedly expressed in NPCs in the
normal brain and plays a role in NPC growth, a substantial
elevation of FOXM1 during gliomagenesis and elevated sensi-
tivity of GSCs over NPCs to pharmacological inhibition of
FOXM1 signaling indicate that GSCs are more dependent on
FOXM1 signaling for their survival and growth. Thus, target-
ing the ability of FOXM1 to form a protein complex with
MELK may represent a potential therapeutic benefit for
GBM. The results presented here may help to gain further
insights into the biology of GSCs as well as molecular mech-
anism of tumorigenesis and therapy resistance in GBM.
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